Last reviewed · How we verify
Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab (Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab) — ARCAGY/ GINECO GROUP.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab TARGET | Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab | ARCAGY/ GINECO GROUP | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab CI watch — RSS
- Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab CI watch — Atom
- Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab CI watch — JSON
- Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab alone — RSS
Cite this brief
Drug Landscape (2026). Pembrolizumab Injectable Product - Chemotherapy - Bevacizumab — Competitive Intelligence Brief. https://druglandscape.com/ci/pembrolizumab-injectable-product-chemotherapy-bevacizumab. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab